Repository logo
 
Publication

Allergen Immunotherapy in MASK‐Air Users in Real‐Life: Results of a Bayesian Mixed‐Effects Model

2022Journal article Open access
Simple item page
dc.contributor.authorSousa‐Pinto, B
dc.contributor.authorAzevedo, LF
dc.contributor.authorSá‐Sousa, A
dc.contributor.authorVieira, RJ
dc.contributor.authorAmaral, R
dc.contributor.authorKlimek, L
dc.contributor.authorCzarlewski, W
dc.contributor.authorAnto, JM
dc.contributor.authorBedbrook, A
dc.contributor.authorKvedariene, V
dc.contributor.authorVentura, MT
dc.contributor.authorAnsotegui, IJ
dc.contributor.authorBergmann, KC
dc.contributor.authorBrussino, L
dc.contributor.authorCanonica, GW
dc.contributor.authorCardona, V
dc.contributor.authorCarreiro‐Martins, P
dc.contributor.authorCasale, T
dc.contributor.authorCecchi, L
dc.contributor.authorChivato, T
dc.contributor.authorChu, DK
dc.contributor.authorCingi, C
dc.contributor.authorCosta, EM
dc.contributor.authorCruz, AA
dc.contributor.authorDe Feo, G
dc.contributor.authorDevillier, P
dc.contributor.authorFokkens, WJ
dc.contributor.authorGaga, M
dc.contributor.authorGemicioğlu, B
dc.contributor.authorHaahtela, T
dc.contributor.authorIvancevich, JC
dc.contributor.authorIspayeva, Z
dc.contributor.authorJutel, M
dc.contributor.authorKuna, P
dc.contributor.authorKaidashev, I
dc.contributor.authorKraxner, H
dc.contributor.authorLarenas‐Linnemann, DE
dc.contributor.authorLaune, D
dc.contributor.authorLipworth, B
dc.contributor.authorLouis, R
dc.contributor.authorMakris, M
dc.contributor.authorMonti, R
dc.contributor.authorMorais‐Almeida, M
dc.contributor.authorMösges, R
dc.contributor.authorMullol, J
dc.contributor.authorOdemyr, M
dc.contributor.authorOkamoto, Y
dc.contributor.authorPapadopoulos, NG
dc.contributor.authorPatella, V
dc.contributor.authorPham‐Thi, N
dc.contributor.authorRegateiro, FS
dc.contributor.authorReitsma, S
dc.contributor.authorRouadi, PW
dc.contributor.authorSamolinski, B
dc.contributor.authorSova, M
dc.contributor.authorTodo‐Bom, A
dc.contributor.authorTaborda‐Barata, L
dc.contributor.authorTomazic, PV
dc.contributor.authorToppila‐Salmi, S
dc.contributor.authorSastre, J
dc.contributor.authorTsiligianni, I
dc.contributor.authorValiulis, A
dc.contributor.authorWallace, D
dc.contributor.authorWaserman, S
dc.contributor.authorYorgancioglu, A
dc.contributor.authorZidarn, M
dc.contributor.authorZuberbier, T
dc.contributor.authorFonseca, JA
dc.contributor.authorBousquet, J
dc.contributor.authorPfaar, O
dc.date.accessioned2022-03-30T11:52:27Z
dc.date.available2022-03-30T11:52:27Z
dc.date.issued2022
dc.description.abstractBackground: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClin Transl Allergy . 2022 Mar;12(3):e12128pt_PT
dc.identifier.doi10.1002/clt2.12128pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4019
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.subjectAllergic rhinitispt_PT
dc.subjectImmunotherapypt_PT
dc.subjectMobile healthpt_PT
dc.subjectPatient-reported outcomespt_PT
dc.subjectReal-life data analysis.pt_PT
dc.subjectHDE ALERpt_PT
dc.titleAllergen Immunotherapy in MASK‐Air Users in Real‐Life: Results of a Bayesian Mixed‐Effects Modelpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue3pt_PT
oaire.citation.startPagee12128pt_PT
oaire.citation.titleClinical and Translational Allergypt_PT
oaire.citation.volume12pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clin Transl Allergy 2022_e12128.pdf
Size:
379.26 KB
Format:
Adobe Portable Document Format
Download

Collections

ALER - Artigos